Abstract
The clinical usefulness of 8 potential tumour markers has been evaluated in 69 patients with Stage I and II breast cancer and 57 patients with Stage III and IV. Serum CEA concentrations were raised in 13% of patients with local and 65% of those with advanced breast cancer. In patients with clinical evidence of progression or regression of tumour, serum CEA levels changed appropriately in 83% of cases. Taking 4 of the markers (carcinoembryonic antigen (CEA), lactalbumin, alpha subunit and haptoglobin) serum concentrations of one or more were raised in 33% of patients with local disease and 81% of those with advanced breast cancer. However, marker concentrations were often only marginally raised, and are unlikely to provide sensitive guide to tumour burden. CEA, lactalbumin and alpha subunit were detectable in 68%, 43% and 40% respectively of extracts of primary breast cancers.
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Cove, D., Woods, K., Smith, S. et al. Tumour markers in breast cancer. Br J Cancer 40, 710–718 (1979). https://doi.org/10.1038/bjc.1979.251
Issue Date:
DOI: https://doi.org/10.1038/bjc.1979.251
- Springer Nature Limited
This article is cited by
-
Prospective assessment of the role of five tumour markers in breast cancer
Cancer Immunology Immunotherapy (1991)
-
The detection and evaluation of human tumor metastases
CANCER AND METASTASIS REVIEW (1983)
-
Evaluation of follow-up methods to detect relapse after mastectomy in breast cancer patients
Irish Journal of Medical Science (1982)
-
Carcino-embryonic antigen assay as a guide to tumour bulk, response to therapy and prognosis in human breast cancer
Irish Journal of Medical Science (1980)